Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB445 in Advanced Solid Tumors
NCT06826040Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Antibody-Drug Conjugates (ADCs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SKB445 in solid tumor, sponsored by Kelun-Biotech. Primary endpoint: Dose-limiting toxicity at 21 days. Started Feb 2025; status: recruiting.
02
Drugs
SKB445
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06826040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826040.